Objective To review studies conducted to evaluate the risk of type 2 diabetes in patients treated with different antipsychotic drugs (AP). Methods a MEDLINE search (January 1985–February 2003) was conducted to establish the potential relationship between the exposure to AP (conventional and second generation) and the development of type 2 diabetes. Studies were classified according to their experimental design as prospective and retrospective (incidence and prevalence based). Results Twenty-one studies were selected: nine prospective and eleven retrospective. Data Synthesis and Conclusions Patients with schizophrenia treated with different AP have an increased risk of developing type 2 diabetes compared with the general population. The data so far available, however, do not establish whether the increasing risk of developing diabetes is a function of the schizophrenia itself or is induced by the antipsychotic treatment. A number of methodological flaws in the study design and data collection do not allow conclusions to be drawn on the risk between patients treated with conventional drugs versus those treated with new ones. Copyright#2004 JohnWiley & Sons, Ltd. key words—clozapine; olanzapine; risperidone; quetiapine; type 2 diabetes; antipsychotic drugs

Antipsychotic drugs and risk of type 2 diabetes: an evidence-based approach

BELLANTUONO, Cesario;
2004

Abstract

Objective To review studies conducted to evaluate the risk of type 2 diabetes in patients treated with different antipsychotic drugs (AP). Methods a MEDLINE search (January 1985–February 2003) was conducted to establish the potential relationship between the exposure to AP (conventional and second generation) and the development of type 2 diabetes. Studies were classified according to their experimental design as prospective and retrospective (incidence and prevalence based). Results Twenty-one studies were selected: nine prospective and eleven retrospective. Data Synthesis and Conclusions Patients with schizophrenia treated with different AP have an increased risk of developing type 2 diabetes compared with the general population. The data so far available, however, do not establish whether the increasing risk of developing diabetes is a function of the schizophrenia itself or is induced by the antipsychotic treatment. A number of methodological flaws in the study design and data collection do not allow conclusions to be drawn on the risk between patients treated with conventional drugs versus those treated with new ones. Copyright#2004 JohnWiley & Sons, Ltd. key words—clozapine; olanzapine; risperidone; quetiapine; type 2 diabetes; antipsychotic drugs
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11566/35153
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact